| 摘要 |
The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the &bgr;-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of &bgr;-amyloid aggregates. |
